Tissue-selective inhibition of cholesterol synthesis in vivo by pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor

This publication has 20 references indexed in Scilit:

• Long-term treatment of hypercholesterolemic non-insulin dependent diabetics (NIDDM) with pravastatin (CS-514)
  Atherosclerosis, 1989
• Preventive effect of pravastatin sodium, a potent inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on coronary atherosclerosis and xanthoma in WHHL rabbits
  Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1988
• CS-514 Suppresses Plasma Triglyceride in Hypertriglyceridemic Subjects Without Modifying a Lipoprotein Structural Model
  Hormone and Metabolic Research, 1987
• PROBUCOL VERSUS EPTASTATIN IN HYPERCHOLESTEROLAEMIC DIABETICS
  The Lancet, 1986
• The Effect of CS-514, an Inhibitor of HMG-CoA Reductase, on Serum Lipids in Healthy Volunteers
  Atherosclerosis, 1986
• CS-514, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase: tissue-selective inhibition of sterol synthesis and hypolipidemic effect on various animal species
  Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1986
• Microbial hydroxylation of ML-236B (compactin) and monacolin K (MB-530B)
  The Journal of Antibiotics, 1983
• Microbial hydroxylation of ML-236B (compactin) Studies on microorganisms capable of 3.BETA.-hydroxylation of ML-236B.
  The Journal of Antibiotics, 1983
• Regulation of HMG-CoA Reductase
  Published by Elsevier ,1976
• ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogensis produced by Penicillium citrinum.
  The Journal of Antibiotics, 1976